Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
Top Cited Papers
Open Access
- 18 October 2004
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 127 (3), 348-355
- https://doi.org/10.1111/j.1365-2141.2004.05202.x
Abstract
Heart failure from iron overload causes 71% of deaths in thalassaemia major, yet reversal of siderotic cardiomyopathy has been reported. In order to determine the changes in myocardial iron during treatment, we prospectively followed thalassaemia patients commencing intravenous desferrioxamine for iron-induced cardiomyopathy during a 12-month period. Cardiovascular magnetic resonance assessments were performed at baseline, 3, 6 and 12 months of treatment, and included left ventricular (LV) function and myocardial and liver T2*, which is inversely related to iron concentration. One patient died. The six survivors showed progressive improvements in myocardial T2* (5·1 ± 1·9 to 8·1 ± 2·8 ms, P = 0·003), liver iron (9·6 ± 4·3 to 2·1 ± 1·5 mg/g, P = 0·001), LV ejection fraction (52 ± 7·1% to 63 ± 6·4%, P = 0·03), LV volumes (end diastolic volume index 115 ± 17 to 96 ± 3 ml, P = 0·03; end systolic volume index 55 ± 16 to 36 ± 6 ml, P = 0·01) and LV mass index (106 ± 14 to 95 ± 13, P = 0·01). Iron cleared more slowly from myocardium than liver (5·0 ± 3·3% vs. 39 ± 23% per month, P = 0·02). These prospective data confirm that siderotic heart failure is often reversible with intravenous iron chelation with desferrioxamine. Myocardial T2* improves in concert with LV volumes and function during recovery, but iron clearance from the heart is considerably slower than from the liver.Keywords
This publication has 29 references indexed in Scilit:
- Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady‐state free precession imaging sequencesJournal of Magnetic Resonance Imaging, 2003
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyThe New England Journal of Medicine, 2000
- Survival and Disease Complications in Thalassemia MajorAnnals of the New York Academy of Sciences, 1998
- Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia MajorThe New England Journal of Medicine, 1994
- Low molecular weight iron and the oxygen paradox in isolated rat hearts.JCI Insight, 1992
- Prolonged survival in patients with beta-thalassemia major treated with deferoxamineThe Journal of Pediatrics, 1991
- Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overloadJournal of the American College of Cardiology, 1986
- DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJORThe Lancet, 1984
- Magnetic-Susceptibility Measurement of Human Iron StoresThe New England Journal of Medicine, 1982
- EVALUATION OF CARDIAC FUNCTION IN PATIENTS WITH THALASSEMIA MAJORAnnals of the New York Academy of Sciences, 1980